These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18536113)

  • 1. Bibliography. Current world literature. HDL cholesterol.
    Curr Opin Cardiol; 2008 Jul; 23(4):426-9. PubMed ID: 18536113
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel targets that affect high-density lipoprotein metabolism: the next frontier.
    Davidson MH; Rosenson RS
    Am J Cardiol; 2009 Nov; 104(10 Suppl):52E-7E. PubMed ID: 19895945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Of mice and men: blowing away the cobwebs from the mechanism of action of niacin on HDL metabolism.
    Watts GF; Chan DC
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):1892-5. PubMed ID: 18946055
    [No Abstract]   [Full Text] [Related]  

  • 5. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
    van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-density lipoprotein cholesterol: current perspective for clinicians.
    Whayne TF
    Angiology; 2009; 60(5):644-9. PubMed ID: 19240106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On call. In your January 2007 article on cholesterol, you said that no-flush niacin does not lower cholesterol levels. But my problem is low HDL cholesterol. Will no-flush niacin help my HDL even if it won't lower my LDL cholesterol?
    Simon HB
    Harv Mens Health Watch; 2007 Jun; 11(11):7-8. PubMed ID: 17644843
    [No Abstract]   [Full Text] [Related]  

  • 8. Bibliography. Current world literature. HDL cholesterol.
    Curr Opin Cardiol; 2005 Jul; 20(4):365-8. PubMed ID: 16124142
    [No Abstract]   [Full Text] [Related]  

  • 9. [Diabetic dyslipoproteinemia: beyond LDL].
    Merkel M
    Dtsch Med Wochenschr; 2009 May; 134(20):1067-73. PubMed ID: 19421932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Significance of HDL cholesterol increase for the risk reduction. Methods of intervention. recommendations of experts].
    Kardiol Pol; 2005 Jun; 62 Suppl 2():II5-12. PubMed ID: 19813328
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessing niacin as an atherosclerosis therapeutic agent valuable insights provided by high-resolution vascular magnetic resonance imaging.
    Jaffer FA
    J Am Coll Cardiol; 2009 Nov; 54(19):1795-6. PubMed ID: 19874993
    [No Abstract]   [Full Text] [Related]  

  • 12. HDL-cholesterol: is it really good? Differences between apoA-I and HDL.
    Santos-Gallego CG; Ibanez B; Badimon JJ
    Biochem Pharmacol; 2008 Aug; 76(4):443-52. PubMed ID: 18547543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FPIN's clinical inquiries. Best alternatives to statins for treating hyperlipidemia.
    Bouknight P; Mackler L; Heffington M
    Am Fam Physician; 2007 Oct; 76(7):1027-9. PubMed ID: 17956075
    [No Abstract]   [Full Text] [Related]  

  • 14. Powerful HDL booster available OTC.
    Health News; 2005 Apr; 11(4):5. PubMed ID: 15818764
    [No Abstract]   [Full Text] [Related]  

  • 15. Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform.
    Rano TA; Sieber-McMaster E; Pelton PD; Yang M; Demarest KT; Kuo GH
    Bioorg Med Chem Lett; 2009 May; 19(9):2456-60. PubMed ID: 19339179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bibliography. Current world literature. Clinical trials.
    Curr Opin Cardiol; 2008 Jul; 23(4):407-21. PubMed ID: 18520727
    [No Abstract]   [Full Text] [Related]  

  • 17. High-density lipoprotein: a fall from grace?
    van Leuven SI; Stroes ES; Kastelein JJ
    Ann Med; 2008; 40(8):584-93. PubMed ID: 18608128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic effect of etofyllinclofibrate in disordered lipid and uric acid metabolism].
    Fiegel G
    Med Welt; 1982 Mar; 33(9):334-6. PubMed ID: 7045566
    [No Abstract]   [Full Text] [Related]  

  • 19. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
    Neeli H; Rader DJ
    Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line therapies for lowering triglyceride levels.
    Raghavan VA
    Am Fam Physician; 2008 Feb; 77(4):416; author reply 417-8. PubMed ID: 18326158
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.